BR112022020107A2 - Métodos de tratamento da síndrome respiratória aguda grave - Google Patents

Métodos de tratamento da síndrome respiratória aguda grave

Info

Publication number
BR112022020107A2
BR112022020107A2 BR112022020107A BR112022020107A BR112022020107A2 BR 112022020107 A2 BR112022020107 A2 BR 112022020107A2 BR 112022020107 A BR112022020107 A BR 112022020107A BR 112022020107 A BR112022020107 A BR 112022020107A BR 112022020107 A2 BR112022020107 A2 BR 112022020107A2
Authority
BR
Brazil
Prior art keywords
methods
acute respiratory
respiratory syndrome
severe acute
treatment
Prior art date
Application number
BR112022020107A
Other languages
English (en)
Portuguese (pt)
Inventor
Hepner Adrian
Original Assignee
Eagle Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eagle Pharmaceuticals Inc filed Critical Eagle Pharmaceuticals Inc
Publication of BR112022020107A2 publication Critical patent/BR112022020107A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR112022020107A 2020-04-10 2021-04-08 Métodos de tratamento da síndrome respiratória aguda grave BR112022020107A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063008529P 2020-04-10 2020-04-10
US202063062623P 2020-08-07 2020-08-07
PCT/US2021/026303 WO2021207444A1 (en) 2020-04-10 2021-04-08 Methods of treating severe acute respiratory syndrome

Publications (1)

Publication Number Publication Date
BR112022020107A2 true BR112022020107A2 (pt) 2022-11-29

Family

ID=75690705

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022020107A BR112022020107A2 (pt) 2020-04-10 2021-04-08 Métodos de tratamento da síndrome respiratória aguda grave

Country Status (11)

Country Link
US (1) US12582633B2 (https=)
EP (1) EP4132516A1 (https=)
JP (1) JP2023521162A (https=)
KR (1) KR20220167292A (https=)
CN (1) CN115916189A (https=)
AU (1) AU2021254415A1 (https=)
BR (1) BR112022020107A2 (https=)
CA (1) CA3174684A1 (https=)
IL (1) IL296518A (https=)
MX (1) MX2022012707A (https=)
WO (1) WO2021207444A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12605364B2 (en) * 2020-04-10 2026-04-21 Eagle Pharmaceuticals, Inc. Methods of treating SARS-CoV-2 infections

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY201417A (en) 2017-10-20 2024-02-21 Eagle Res Labs Limited Dantrolene prodrugs and methods of their use
US11123328B2 (en) 2017-11-14 2021-09-21 University Health Network Dantrolene and analogs thereof for the chronic treatment and prevention of dyssynchronous cardiac dysfunction
WO2019175761A1 (en) 2018-03-12 2019-09-19 Orbicular Pharmaceutical Technologies Private Limited Ready to use dantrolene compositions
US12246028B2 (en) 2018-11-27 2025-03-11 Eagle Research Labs Limited Use of dantrolene and dantrolene prodrugs to treat radiation exposure
US12605364B2 (en) 2020-04-10 2026-04-21 Eagle Pharmaceuticals, Inc. Methods of treating SARS-CoV-2 infections

Also Published As

Publication number Publication date
US12582633B2 (en) 2026-03-24
EP4132516A1 (en) 2023-02-15
WO2021207444A1 (en) 2021-10-14
CA3174684A1 (en) 2021-10-14
AU2021254415A1 (en) 2022-10-20
US20230149363A1 (en) 2023-05-18
IL296518A (en) 2022-11-01
CN115916189A (zh) 2023-04-04
KR20220167292A (ko) 2022-12-20
MX2022012707A (es) 2023-01-05
JP2023521162A (ja) 2023-05-23

Similar Documents

Publication Publication Date Title
CO2020013600A2 (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
MX2023008453A (es) Metodos de tratamiento para el abuso de sustancias.
CL2019003126A1 (es) Métodos de tratamiento mediante el uso de un compuesto inhibidor de jak.
MX387115B (es) Métodos para tratar la influenza.
EP4497474A3 (en) Methods of treating rheumatic diseases using trimetazidine-based compounds
BR112019002730A2 (pt) acetil-leucina, ou um sal farmaceuticamente aceitável da mesma, para uso em um método de tratamento de uma doença neurodegenetativa
EA202193015A1 (ru) Ингибиторы cdk
MX2022013172A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
MX2017015226A (es) Compuestos alqueno tetrasustituidos y su uso.
BR112022002609A2 (pt) Métodos de tratamento de tumores estromais gastrointestinais
MX385283B (es) Tratamiento de cáncer usando 2-desoxi-2-fluoro-l-fucosa en combinación con un inhibidor del punto de control.
BR112021011325A2 (pt) Derivados de rapamicina
MX387658B (es) Métodos para tratar y/o prevenir queratosis actínica.
BR112019004236A2 (pt) compostos para tratar doenças associadas a uma disfunção mitocondrial
MX394245B (es) Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia.
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
CO2019009000A2 (es) Combinaciones farmacéuticas para tratar cáncer
BR112021020962A2 (pt) Métodos de tratamento de prurido
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
CL2021000531A1 (es) Métodos de uso de un compuesto de fenoxipropilamina para tratar el dolor.
MX380758B (es) Compuesto que tiene actividad inhibitoria de idh mutante, método de preparación y usos del mismo.
EA202193276A1 (ru) Способы лечения холангиокарциномы
BR112022020107A2 (pt) Métodos de tratamento da síndrome respiratória aguda grave
BR112019004791A2 (pt) tratamento de esclerose múltipla com chs-131
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.